EP1071459A4 - Methods to provoke anti-cancer immune responses - Google Patents

Methods to provoke anti-cancer immune responses

Info

Publication number
EP1071459A4
EP1071459A4 EP99912724A EP99912724A EP1071459A4 EP 1071459 A4 EP1071459 A4 EP 1071459A4 EP 99912724 A EP99912724 A EP 99912724A EP 99912724 A EP99912724 A EP 99912724A EP 1071459 A4 EP1071459 A4 EP 1071459A4
Authority
EP
European Patent Office
Prior art keywords
methods
immune responses
cancer immune
provoke
provoke anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912724A
Other languages
German (de)
French (fr)
Other versions
EP1071459A1 (en
Inventor
Bruce L Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1071459A1 publication Critical patent/EP1071459A1/en
Publication of EP1071459A4 publication Critical patent/EP1071459A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
EP99912724A 1998-03-20 1999-03-19 Methods to provoke anti-cancer immune responses Withdrawn EP1071459A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7893198P 1998-03-20 1998-03-20
US78931P 1998-03-20
PCT/US1999/006048 WO1999047169A1 (en) 1998-03-20 1999-03-19 Methods to provoke anti-cancer immune responses

Publications (2)

Publication Number Publication Date
EP1071459A1 EP1071459A1 (en) 2001-01-31
EP1071459A4 true EP1071459A4 (en) 2002-07-17

Family

ID=22147094

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912724A Withdrawn EP1071459A4 (en) 1998-03-20 1999-03-19 Methods to provoke anti-cancer immune responses

Country Status (5)

Country Link
EP (1) EP1071459A4 (en)
JP (1) JP2002506832A (en)
AU (1) AU755706B2 (en)
CA (1) CA2322969A1 (en)
WO (1) WO1999047169A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
AU6497799A (en) * 1998-10-15 2000-05-01 Canji, Inc. Methods and compositions to induce antitumor response
US20020006397A1 (en) * 2000-04-28 2002-01-17 Roberts Bruce L. In VIVO loading of MHC

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US6080383A (en) * 1997-01-13 2000-06-27 Rose; Samuel Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BUEELER H ET AL: "INDUCTION OF ANTIGEN-SPECIFIC TUMOR IMMUNITY BY GENETIC AND CELLULAR VACCINES AGAINST MAGE: ENHANCED TUMOR PROTECTION BY COEXPRESSION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND B7-1", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 2, no. 5, 1 September 1996 (1996-09-01), pages 545 - 555, XP002035094, ISSN: 1076-1551 *
CHEN S-H ET AL: "COMBINATION GENE THERAPY FOR LIVER METASTASIS OF COLON CARCINOMA INVIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 7, 1995, pages 2577 - 2581, XP000604926, ISSN: 0027-8424 *
DOWELL R I ET AL: "NEW MUSTARD PRODRUGS FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY: ALTERNATIVES TO THE AMIDE LINK", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 39, no. 5, 1996, pages 1100 - 1105, XP002027294, ISSN: 0022-2623 *
IWADATE YASUO ET AL: "Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene ganciclovir administration.", ONCOLOGY (BASEL), vol. 54, no. 4, 1997, pages 329 - 334, XP001070213, ISSN: 0030-2414 *
LINDAUER M ET AL: "GENE TRANSFER OF COSTIMULATORY MOLECULES INTO A HUMANCOLORECTAL CANCER CELL LINE: REQUIREMENT OF CD54, CD80 AND CLASS II MHC EXPRESSION FOR ENHANCED IMMUNOGENICITY", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 93, no. 3, March 1998 (1998-03-01), pages 390 - 397, XP000876810, ISSN: 0019-2805 *
NICULESCU-DUVAZ I ET AL: "GENE-DIRECTED ENZYME PRODRUG THERAPY", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 9, no. 1, 1 March 1998 (1998-03-01), pages 4 - 22, XP000729231, ISSN: 1043-1802 *
OSTRAND-ROSENBERG S ET AL: "TUMOR-SPECIFIC IMMUNITY CAN BE ENHANCED BY TRANSFECTION OF TUMOR CELLS WITH SYNGENEIC MHC-CLASS-II GENES OR ALLOGENEIC MHC-CLASS-I GENES", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, no. SUPPL 6, 1991, pages 61 - 68, XP002065931, ISSN: 0020-7136 *
See also references of WO9947169A1 *
VILE R G ET AL: "SYSTEMIC GENE THERAPY OF MURINE MELANOMA USING TISSUE SPECIFIC EXPRESSION OF THE HSVTK GENE INVOLVES AND IMMUNE COMPONENT", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 23, 1 December 1994 (1994-12-01), pages 6228 - 6234, XP001061699, ISSN: 0008-5472 *
YAMAMOTO SHIRO ET AL: "Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice.", CANCER GENE THERAPY, vol. 4, no. 2, 1997, pages 91 - 96, XP001069247, ISSN: 0929-1903 *
YEE C ET AL: "Prospects for adoptive T cell therapy", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 9, no. 5, October 1997 (1997-10-01), pages 702 - 708, XP004313589, ISSN: 0952-7915 *

Also Published As

Publication number Publication date
JP2002506832A (en) 2002-03-05
WO1999047169A1 (en) 1999-09-23
AU3103699A (en) 1999-10-11
AU755706B2 (en) 2002-12-19
EP1071459A1 (en) 2001-01-31
CA2322969A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
HUP0103085A3 (en) Formulations an processes for inducing an immune response to polysaccharide
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
AU2002225512A1 (en) Immune system stimulation
EP0999847A4 (en) Health supplement
HUP0104031A3 (en) Novel process to prepare microencapsulated formulations
GB0100777D0 (en) Device related to risers
AU1702102A (en) Device for connecting to each other three flat elements
HUP0201222A3 (en) Use of soluble constimulatory molecules to enhance immune responses
HU9902702D0 (en) Device to stop lift
EP1071459A4 (en) Methods to provoke anti-cancer immune responses
PL319735A1 (en) Natural antioxidative preparation
AU2002239441A1 (en) Methods and compositions for inducing cell-mediated immune responses
GB9716924D0 (en) Improvements relating to nerve testing devices
IL157614A0 (en) Uses of opg ligand to modulate immune responses
AU6604701A (en) Method to induce the TH1 immune response
EP1114059A4 (en) Regulation of immune responses by attractin
GB2351905B (en) Eliciting improved immune responses
GB9807062D0 (en) Immune response
GB9822619D0 (en) Immune response stimulation
IL126464A (en) Water-binding composition for foods
GB2333938B (en) Improvements to cultivator
GB9930294D0 (en) Improvements in or relating to immune responses to HIV
GB0025234D0 (en) Improvements in or relating to immune responses to HIV
GB9727410D0 (en) Improvements relating to adjustable furniture
GB9727230D0 (en) Improvements relating to adjustable furniture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20021219